Allspring Global Investments Holdings LLC Has $2.91 Million Position in Catalyst Pharmaceuticals, Inc. $CPRX

Allspring Global Investments Holdings LLC boosted its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 428.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 117,088 shares of the biopharmaceutical company’s stock after buying an additional 94,933 shares during the quarter. Allspring Global Investments Holdings LLC owned approximately 0.10% of Catalyst Pharmaceuticals worth $2,906,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of CPRX. Deerfield Management Company L.P. boosted its holdings in shares of Catalyst Pharmaceuticals by 72.8% in the 3rd quarter. Deerfield Management Company L.P. now owns 4,974,767 shares of the biopharmaceutical company’s stock worth $98,003,000 after acquiring an additional 2,095,291 shares in the last quarter. Janus Henderson Group PLC boosted its stake in Catalyst Pharmaceuticals by 200.6% in the fourth quarter. Janus Henderson Group PLC now owns 1,719,767 shares of the biopharmaceutical company’s stock worth $40,124,000 after purchasing an additional 1,147,565 shares in the last quarter. Morgan Stanley boosted its stake in Catalyst Pharmaceuticals by 59.1% in the fourth quarter. Morgan Stanley now owns 2,933,399 shares of the biopharmaceutical company’s stock worth $68,466,000 after purchasing an additional 1,089,775 shares in the last quarter. Glenmede Investment Management LP grew its holdings in shares of Catalyst Pharmaceuticals by 781.8% during the third quarter. Glenmede Investment Management LP now owns 680,224 shares of the biopharmaceutical company’s stock worth $13,400,000 after purchasing an additional 603,084 shares during the last quarter. Finally, Bank of America Corp DE lifted its position in Catalyst Pharmaceuticals by 30.6% during the 2nd quarter. Bank of America Corp DE now owns 2,365,675 shares of the biopharmaceutical company’s stock worth $51,335,000 after buying an additional 554,200 shares in the last quarter. 79.22% of the stock is currently owned by institutional investors.

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ CPRX opened at $31.49 on Friday. Catalyst Pharmaceuticals, Inc. has a 52-week low of $19.05 and a 52-week high of $32.56. The stock has a market cap of $3.86 billion, a P/E ratio of 18.10, a P/E/G ratio of 0.96 and a beta of 0.74. The firm has a 50 day moving average price of $31.39 and a 200 day moving average price of $27.30.

Wall Street Analyst Weigh In

CPRX has been the subject of a number of research reports. Zacks Research lowered shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, May 18th. Robert W. Baird lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 7th. Weiss Ratings raised Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, June 3rd. Oppenheimer lowered Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 7th. Finally, Wall Street Zen cut Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $32.00.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).